Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis.

"Declarations Conflict of interestC. Fiehn has received consulting fees from AbbVie, Ablynx, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, MSD, Medac, Novartis, Pfizer, Roche, Sanofi, and UCB. S. Zinke has been an investigator for clinical trials for or received lecture or consulting fees from AbbVie, Galapagos, Janssen, Lilly, Novartis, Pfizer, and UCB. J.S. Haas, D. Meise and J. Theil are employees of Xcenda GmbH, a company that received funding from Gilead Sciences to conduct this study. M. Gurrath and H.-D. Orzechowski are employees of Galapagos, former employees of Gilead Sciences, and own Gilead stock. Anonymized statutory health insurance data were used for this study. The use of such data is not subject to ethics committee approval in Germany. Consent for publication: not applicable. Conflict of interest C. Fiehn has received consulting fees from AbbVie, Ablynx, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, MSD, Medac, Novartis, Pfizer, Roche, Sanofi, and UCB. S. Zinke has been an investigator for clinical trials for or received lecture or consulting fees from AbbVie, Galapagos, Janssen, Lilly, Novartis, Pfizer, and UCB. J.S. Haas, D. Meise and J. Theil are employees of Xcenda GmbH, a company that received funding from Gilead Sciences to conduct this study. M. Gurrath and H.-D. Orzechowski are employees of Galapagos, former employees of Gilead Sciences, and own Gilead stock."

"Funding This study was sponsored by Gilead Sciences (Foster City, CA, USA). Medical writing support was funded by Galapagos NV (Mechelen, Belgium)."